

Special Issue

Advances in the Medical Treatment of Diabetic Retinopathy

Message from the Guest Editor

Diabetic retinopathy is a prevalent diabetic complication with important social and budgetary repercussions. Treatments such as intravitreal injections and laser photocoagulation are focused on the late stages of the disease, but there is no specific treatment for the early stages. Moreover, in advanced retinal disease, when a diabetic macular edema is present, the response to intravitreal injections, which are invasive, is heterogeneous, and more personalized medicine is needed. New approaches and new therapeutic targets, as well as new drug delivery forms in diabetic retinopathy treatment, have arisen in recent years. The aim of this Special Issue of *Pharmaceutics* is to compile high-quality papers related to the medical treatment of diabetic retinopathy (clinical or experimental), with especial emphasis on the early stages of the disease. Papers (review articles or original research) focusing on new therapeutic targets, new drug delivery forms or a personalized management of diabetic retinopathy will be welcome in this Special Issue.

Guest Editor

Dr. Olga Simó-Servat

Endocrinology Department, Vall d'Hebron University Hospital, Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute (VHIR), ans CIBERDEM (ISCIII), 08035 Barcelona, Spain

Deadline for manuscript submissions

closed (20 May 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 6.9
CiteScore 12.5
Indexed in PubMed



mdpi.com/si/105819

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 6.9
CiteScore 12.5
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).